Pediatric erythroblastic transformation of JAK2-mutated prefibrotic primary myelofibrosis with concurrent PHF6 mutations

Pediatr Blood Cancer. 2023 Oct;70(10):e30508. doi: 10.1002/pbc.30508. Epub 2023 Jun 19.

Authors

Tokiko Oshiro¹, Satoru Hamada¹, Sinobu Kiyuna¹, Hideki Sakiyama¹, Nobuyuki Hyakuna², Tomoko Tamaki³, Hideki Muramatsu⁴, Koichi Nakanishi⁵

Affiliations

¹ Department of Pediatrics, University of Ryukyus Hospital, Nakagami-gun, Japan.
² Okinawa Prefectural Red Cross Blood Center, Naha, Japan.
³ Department of Pathology and Oncology, Graduate School of Medicine, University of Ryukyus, Nakagami-gun, Japan.
⁴ Department of Pediatrics, Graduate School of Medicine, University of Nagoya, Nagoya, Japan.
⁵ Department of Pediatrics, Graduate School of Medicine, University of The Ryukyus, Nakagami-gun, Japan.

PMID: 37337098
DOI: 10.1002/pbc.30508

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Bone Marrow
Calreticulin / genetics
Humans
Janus Kinase 2 / genetics
Male
Mutation
Primary Myelofibrosis* / genetics
Repressor Proteins / genetics

Substances

Calreticulin
JAK2 protein, human
Janus Kinase 2
PHF6 protein, human
Repressor Proteins